No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
TWST Twist Bioscience
- 49.840
- -2.190-4.21%
Close Jun 14 16:00 ET
- 49.700
- -0.140-0.28%
Post 19:31 ET
2.90BMarket Cap-14833P/E (TTM)
51.520High49.190Low968.25KVolume50.880Open52.030Pre Close48.38MTurnover1.69%Turnover RatioLossP/E (Static)58.23MShares55.26052wk High5.18P/B2.86BFloat Cap14.42052wk Low--Dividend TTM57.33MShs Float214.070Historical High--Div YieldTTM4.48%Amplitude11.460Historical Low49.968Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Here's Why We're Not At All Concerned With Twist Bioscience's (NASDAQ:TWST) Cash Burn Situation
Twist Bioscience Is Maintained at Buy by TD Cowen
Twist Bioscience Is Maintained at Buy by TD Cowen
TD Cowen Maintains Twist Bioscience(TWST.US) With Buy Rating, Maintains Target Price $65
TD Cowen analyst Steven Mah maintains $Twist Bioscience(TWST.US)$ with a buy rating, and maintains the target price at $65.According to TipRanks data, the analyst has a success rate of 25.8% and a tot
Express News | Twist Bioscience Corp : TD Cowen Raises Target Price to $65 From $55
TD Cowen Maintains Twist Bioscience(TWST.US) With Buy Rating, Raises Target Price to $65
TD Cowen analyst Steven Mah maintains $Twist Bioscience(TWST.US)$ with a buy rating, and adjusts the target price from $55 to $65.According to TipRanks data, the analyst has a success rate of 25.8% an
Barclays Maintains Twist Bioscience(TWST.US) With Buy Rating, Maintains Target Price $45
Barclays analyst Luke Sergott maintains $Twist Bioscience(TWST.US)$ with a buy rating, and maintains the target price at $45.According to TipRanks data, the analyst has a success rate of 42.3% and a t
Comments
How does the biotech ecosystem support advancements in personalized medicine & genomics? ![]()
• Editing Genes | $CRISPR Therapeutics(CRSP.US$ , $Intellia Therapeutics(NTLA.US$ , $Beam Therapeutics(BEAM.US$ , $Verve Therapeutics(VERV.US$ , $Editas Medicine(EDIT.US$
• Creating Therapies | $Prime Medicine(PRME.US$ , $Sana Biotechnology(SANA.US$
• Building DNA | $Twist Bioscience(TWST.US$ , $Ginkgo Bioworks(DNA.US$ , $Pacific Biosciences of California(PACB.US$ , $Illumina(ILMN.US$
• Dis...
• Editing Genes | $CRISPR Therapeutics(CRSP.US$ , $Intellia Therapeutics(NTLA.US$ , $Beam Therapeutics(BEAM.US$ , $Verve Therapeutics(VERV.US$ , $Editas Medicine(EDIT.US$
• Creating Therapies | $Prime Medicine(PRME.US$ , $Sana Biotechnology(SANA.US$
• Building DNA | $Twist Bioscience(TWST.US$ , $Ginkgo Bioworks(DNA.US$ , $Pacific Biosciences of California(PACB.US$ , $Illumina(ILMN.US$
• Dis...
6
Twist Bioscience's P/S ratio remains lower due to sub-par revenue outlook, indicating investor expectation of limited future growth. Shareholder pessimism around future revenue growth contributes to this lower ratio.
Twist Bioscience's optimistic cash runway and manageable burn rate are noteworthy despite the need for vigilance as the firm grows. Its market cap also points to easy fundraising potential.
Despite Twist Bioscience's unprofitability, rapid revenue growth indicates positive prospects. However, persistent share price decline hints at capital raising issues. Investors should assess the firm's balance sheet, market conditions and specific risks.
$Twist Bioscience(TWST.US$ Twist Bioscience Announced An Antibody Discovery, Option And License Agreement With Bayer Of Up To $188M. Bayer Will Have The Option To License Antibodies Discovered Under The Collaboration
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg